Table 4: Individualized application plan for each patient.
 AntibioticAntipyreticArg. m. p. D30Echinacea D6Ferr. sid.
D20		Millefolium D4Ferr. phos. D6Equisetum D20Petasites D3Prunus spi. D3Sticta pulm D3Tartarus stibiatus D4Bryonia D4GelomyrtolCarb. bet. D20Ginger
Millefol.
Cochlearia
Mustard
Potatoes
Application  s. c.s. c./p. o.s. c.s. c.s. c.s. c.p. o.p. o.p. o.s. c.p. o.p. o.s. c.Ext.Ext.Ext.Ext.Ext.
Patient Nr                    
1  +  +  +     + +   
2   + +  +      ++   
3Pretreated ++   +++    +++   
4     + D15+  ++ +++ + 
5  ++D10 D10+   D6    + + 
6  ++ + D3 Dil.D6  +  +++   
7+ ++ +  ++  Dil. +++   
8    D10   D2   +  +    
9++   +              
10   + ++ D6 +++ ++   +
11Pretreated ++ +  D6 +   +++   
12   + +  ++++ ++   + 
13Pretreated    +              
14  ++ +  D2 and D6 +    +    
15Pretreated ++  +  D6+  +  +   +
16  ++ +  +++ Dil.++++   
17  +  +  D2   Dil.++++   
18  D8+ +  ++  Dil.   +   
19    D10   +  +       +
20    D10+  +  ++  ++  +
21  ++ +  +    +++    
22   + +  +++   ++++  
23  ++ ++  + + + +++++ 
24  ++ +  +   + +++   
25  ++ +  ++  Dil.  ++ + 
26    ++  +      +  + 
This table shows the individual therapy plan of each patient. Peroral (p.o.) and subcutaneous medication (s.c.) is outlined as well as external applications (Ext.). We omitted the illustration of convential co-medication. If the applied homeopathic potencies differed from the described in the headline, it was particularly outlined in the table. CAP-study group are bold.